Decoy Therapeutics Pursues Pan-Filovirus Antiviral Program for Ebola, Marburg; Shares Rise

Decoy Therapeutics, Inc. (DCOY) said on September 22, 2026, it is expanding its antiviral platform into a pan-filovirus program targeting Ebola and Marburg viruses, pursuing a regulatory pathway with the U.S. Food and Drug Administration. The company's shares rose on the announcement. The biotech said it will seek non-dilutive funding and public health partnerships to support development of the program. No financial terms, timeline or specific FDA submission date were disclosed. Decoy did not provide clinical data or a development schedule. Further details were not immediately available.